Analytical Considerations for a Peptide Conjugated Virus Like Particle
John Amery
Senior Principal Scientist, Pfizer / Biotherapeutics Pharmaceutical Sciences
A Virus Like Particle (VLP) was manufactured from the phage Qbeta capsid protein using recombinant expression and protein purification techniques. This VLP is then activated with a linker and conjugated to a peptide. Methods for supporting the manufacture and release of the peptide and peptide conjugated VLP were developed. Specifics of these methods will be discussed along with how this information was used to progress the project.
John Amery has spent the last 12 years in Biopharmaceutical research and development at Pharmacia and Pfizer. During this time he has been supporting the manufacture, formulation, and testing of recombinant proteins, peptide conjugates, synthetic nucleotides, and polysaccharides. In recent years his focus has been delivering vaccine conjugates and novel adjuvants to the clinic along with CMC documentation to the regulatory agencies. Dr. Amery received his BS (1992) and MS (1996) in BioChemical Engineering from the University of Missouri, Columbia. He received his PhD in Engineering from the University of Nebraska, Lincoln in 2004.